
USD
$0.00
(0.00%
)At Close (As of Nov 5, 2025)
$51.32B
Market Cap
32.38
P/E Ratio
5.53
EPS
$248.00
52 Week High
$161.47
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | $9.1B |
| Total Revenue | $20B |
| Cost Of Revenue | $11B |
| Costof Goods And Services Sold | $11B |
| Operating Income | $2.4B |
| Selling General And Administrative | $4.9B |
| Research And Development | $1.2B |
| Operating Expenses | $6.7B |
| Investment Income Net | - |
| Net Interest Income | -$365M |
| Interest Income | $163M |
| Interest Expense | $528M |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $2.3B |
| Income Before Tax | $2B |
| Income Tax Expense | $300M |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | $1.7B |
| Comprehensive Income Net Of Tax | - |
| Ebit | $2.5B |
| Ebitda | $4.8B |
| Net Income | $1.7B |
| Field | Value (USD) |
|---|---|
| Total Assets | $57B |
| Total Current Assets | $10B |
| Cash And Cash Equivalents At Carrying Value | $1.7B |
| Cash And Short Term Investments | $1.7B |
| Inventory | $3.8B |
| Current Net Receivables | $3B |
| Total Non Current Assets | $47B |
| Property Plant Equipment | $7.7B |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | $11B |
| Intangible Assets Excluding Goodwill | $11B |
| Goodwill | $26B |
| Investments | - |
| Long Term Investments | - |
| Short Term Investments | $445M |
| Other Current Assets | $1.4B |
| Other Non Current Assets | - |
| Total Liabilities | $31B |
| Total Current Liabilities | $9B |
| Current Accounts Payable | $1.9B |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | $2.3B |
| Total Non Current Liabilities | $22B |
| Capital Lease Obligations | - |
| Long Term Debt | $18B |
| Current Long Term Debt | $2.2B |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | $21B |
| Other Current Liabilities | $4.6B |
| Other Non Current Liabilities | $3.6B |
| Total Shareholder Equity | $26B |
| Treasury Stock | - |
| Retained Earnings | $16B |
| Common Stock | $371M |
| Common Stock Shares Outstanding | $291M |
| Field | Value (USD) |
|---|---|
| Operating Cashflow | $3.8B |
| Payments For Operating Activities | - |
| Proceeds From Operating Activities | - |
| Change In Operating Liabilities | - |
| Change In Operating Assets | - |
| Depreciation Depletion And Amortization | $2.3B |
| Capital Expenditures | $725M |
| Change In Receivables | - |
| Change In Inventory | $98M |
| Profit Loss | - |
| Cashflow From Investment | -$5.5B |
| Cashflow From Financing | $2.1B |
| Proceeds From Repayments Of Short Term Debt | - |
| Payments For Repurchase Of Common Stock | - |
| Payments For Repurchase Of Equity | - |
| Payments For Repurchase Of Preferred Stock | - |
| Dividend Payout | $1.1B |
| Dividend Payout Common Stock | $1.1B |
| Dividend Payout Preferred Stock | - |
| Proceeds From Issuance Of Common Stock | - |
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
| Proceeds From Issuance Of Preferred Stock | - |
| Proceeds From Repurchase Of Equity | -$500M |
| Proceeds From Sale Of Treasury Stock | - |
| Change In Cash And Cash Equivalents | - |
| Change In Exchange Rate | - |
| Net Income | $1.7B |
| Field | Value (USD) |
|---|---|
| Gross Profit | $9.1B |
| Total Revenue | $20B |
| Cost Of Revenue | $11B |
| Costof Goods And Services Sold | $11B |
| Operating Income | $2.4B |
| Selling General And Administrative | $4.9B |
| Research And Development | $1.2B |
| Operating Expenses | $6.7B |
| Investment Income Net | - |
| Net Interest Income | -$365M |
| Interest Income | $163M |
| Interest Expense | $528M |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $2.3B |
| Income Before Tax | $2B |
| Income Tax Expense | $300M |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | $1.7B |
| Comprehensive Income Net Of Tax | - |
| Ebit | $2.5B |
| Ebitda | $4.8B |
| Net Income | $1.7B |
| Field | Value |
|---|---|
| Ex Dividend Date | 2025-09-08 |
| Declaration Date | 2025-07-22 |
| Record Date | 2025-09-08 |
| Payment Date | 2025-09-30 |
| Amount | 1.04 |
Sector: HEALTHCARE
Industry: MEDICAL INSTRUMENTS & SUPPLIES
Becton, Dickinson and Company (BDX) is a leading American multinational medical technology company renowned for its development and production of critical medical devices, instrument systems, and reagents that significantly improve global healthcare outcomes. With a diversified portfolio that supports a wide array of diagnostic and therapeutic procedures, BDX effectively addresses the evolving needs of the healthcare community while providing analytical and consulting services to enhance its operational footprint. Driven by a robust commitment to innovation, underscored by considerable investments in research and development, BDX is poised to capitalize on emerging trends in the medical technology sector, solidifying its position as a key player in advancing healthcare solutions.